Cell and Gene Therapy Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Cell and Gene Therapy Market Overview

The market is expanding rapidly, driven by breakthroughs in genetic engineering and rising demand for targeted treatments. Increasing approvals of advanced therapies, including CAR-T therapy, strong clinical pipelines, and growing investments are supporting growth. Advancements in manufacturing and delivery technologies, along with favorable regulatory support, are further accelerating commercialization and global adoption of innovative therapeutic solutions. The market reached a value of approximately USD 21.43 Billion in 2025.

Cell and Gene Therapy Market Growth Drivers

Increasing Regulatory Approvals for Advanced Therapies Driving the Market Value

Rising prevalence of rare diseases and growing regulatory support are key market drivers. For instance, in March 2026, the U.S. FDA approved the first gene therapy for leukocyte adhesion deficiency-I, restoring immune function. This milestone highlights the growing adoption of advanced therapy medicinal product (ATMP) solutions, accelerating commercialization, strengthening clinical confidence, and driving long-term growth in the market.

Cell and Gene Therapy Market Trends

Key trends shaping the market include AI integration, gene editing advances, strategic collaborations, and expanding clinical pipelines globally.

Integration of AI in Therapy Development Shaping Market Landscape

Advancements in digital technologies and increasing R&D investments are shaping market trends. For instance, in October 2025, AstraZeneca partnered with Algen Biotechnologies in a USD 555 million deal to develop gene therapies using AI platforms. This collaboration is expected to enhance CRISPR-Cas9 innovation, optimize discovery timelines, and improve precision, supporting future market expansion.

Cell and Gene Therapy Market Segmentation

Cell and Gene Therapy Market Share

Cell Therapy Manufacturing Expected to Dominate Market Segment by Therapy Type

By therapy type, the cell therapy manufacturing segment dominated the market with a revenue share of above 59% during the historical period, driven by increasing clinical adoption and commercialization of personalized treatments. The growing success of CAR-T therapy in oncology has significantly contributed to segment growth. Additionally, expanding clinical pipelines and investments in production capabilities continue to reinforce its leading position globally.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Cell and Gene Therapy Market Analysis by Region

North America dominated the market with a revenue share of more than 47% during the historical period, supported by advanced healthcare infrastructure and strong regulatory frameworks. The region benefits from significant investments in biotechnology innovation, particularly in CRISPR-Cas9 technologies. Furthermore, the presence of major industry players and robust clinical trial activity continues to drive regional market expansion.

Leading Players in the Cell and Gene Therapy Market

Other key players in the market are Castle Creek Pharmaceutical Holdings, Bristol-Myers Squibb, Kite Pharma, Inc., Vericel Corporation Inc., Kolon TissueGene Inc., Vertex Pharmaceuticals, Inc., Spark Therapeutics, Inc., CORESTEM Inc., Biogen Inc., Dendreon Pharmaceuticals LLC., and JCR Pharmaceuticals Co. Ltd., among others.

Key Questions Answered in the Cell and Gene Therapy Market Report

• What was the cell and gene therapy market value in 2025?
• What is the cell and gene therapy market forecast outlook for 2026-2035?
• What major factors aid the demand for the cell and gene therapy market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major cell and gene therapy market trends?
• Which therapy type is expected to dominate the market segment?
• Which type is expected to dominate the market segment?
• Which delivery mode is expected to dominate the market segment?
• Which vector type is expected to dominate the market segment?
• Which therapeutic area is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the cell and gene therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?